AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: tenofovir/atazanavir/ritonavir dosage #2
Description: tenofovir/atazanavir/ritonavir 300/400/100 mg once a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: nelfinavir dosage #2
Description: nelfinavir \[625 mg tablets\] 1875 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: indinavir/ritonavir dosage #2
Description: indinavir/ritonavir 400/100 mg twice a day
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: rilpivirine
Description: rilpivirine (25 mg q.d.)
Study NCT00042289 — intervention group
Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #4
Description: darunavir/ritonavir once daily 800/100 mg q.d.
Study NCT00488462 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: non-pneumatic anti-shock garment
Description: In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
Study NCT01495117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: 7.5% povidone iodine soaping 10% povidone iodine painting
Study NCT01495117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: 4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
Study NCT00443261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: SC azacitidine
Study NCT00443261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatin 75 mg/m\^2 day 8 every 28 days
Study NCT03159013 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exposure
Description: Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.~Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31.
Study NCT00870038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent
Description: Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
Study NCT00870038 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention: Uncoated balloon + Genous stent
Description: Predilatation with uncoated balloon, the stenting with Genous stent.
Study NCT00870038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention: Drug eluting stent (Taxus stent)
Description: Predilatation with uncoated balloon, the placement of a Taxus stent.
Study NCT04165733 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Online questionnaire
Description: Clinical psychologists in Germany currently working with patients with mental disorders
Study NCT01002742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Oral dosing should be delivered in 250 mg units. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight > 60 kg should receive MMF 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Study NCT01002742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dosing should be delivered in 250 mg units blinded placebo. For those \< 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.~* Patients who weight > 60 kg should receive placebo 1 gm PO/IV every 8 hours.~* Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.~* Patients who weight \<40 kg should receive 20 mg/kg IV or PO every 8 hours.
Study NCT02800772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: acetic acid
Study NCT02800772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT02766907 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreserved amniotic membrane
Description: placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
Study NCT04539691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet
Description: Magnet or Sham is worn by subject in close proximity to their described maximum pain site
Study NCT04539691 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnet
Description: Magnet or Sham is worn by subject in close proximity to their described maximum pain site
Study NCT01351064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHICA ADHD Module
Description: This module was added to CHICA to help diagnose and manage ADHD
Study NCT00869219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevanac
Description: 1 drop of NEVANAC at random eye
Study NCT00869219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acular LS
Description: One drop of Acular LS
Study NCT00168909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alfacalcidol
Description: alfacalcidol 1 µg once daily, oral, for 3 years
Study NCT00168909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily, oral, for 3 years
Study NCT00950976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: citrulline
Description: TID for 5 days
Study NCT00950976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lemonade
Description: TID for 5 days
Study NCT01601951 — intervention group
Intervention type: OTHER
Intervention: Procedural, Bone Marrow concentrate injection
Description: This is strictly data collection and outcomes based. The procedure is not part of this study
Study NCT00643344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Craving and Lifestyle Management through Mindfulness(CALMM+)
Description: MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
Study NCT00643344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Craving and Lifestyle Management through Mindfulness(CALMM+)
Description: MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
Study NCT03222440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study NCT00250081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Extremity Tendon transfer
Study NCT00250081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin injections in Upper Extremity
Study NCT00250081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regularly ongoing therapy
Study NCT03201848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given to subject will be adjusted by body weight (\<10kg, Placebo given to subject will be adjusted by body weight(\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
Study NCT03201848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaiqihuang Granule
Description: Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Study NCT03201848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Huaiqihuang Granule
Description: Huaiqihuang Granule given to subject will be adjusted by body weight (\<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
Study NCT02372097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-472
Description: SYR-472 25mg, 50mg
Study NCT02111967 — intervention group
Intervention type: OTHER
Intervention: Questionnaire administration
Study NCT02111967 — intervention group
Intervention type: OTHER
Intervention: Laboratory biomarker analysis
Study NCT02528253 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Week 16; tanezumab 5mg SC
Description: Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
Study NCT02528253 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Week 16, tanezumab 10 mg SC
Description: Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
Study NCT02528253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg SC
Description: Tanezumab 5 mg SC
Study NCT02528253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg SC
Description: Tanezumab 10 mg SC
Study NCT02528253 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol PR oral
Description: Tramadol PR oral
Study NCT01536652 — intervention group
Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Prescription at the discretion of the treating physician
Study NCT04397029 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureTouch
Description: The first group will consist of 70 women who are believed to be free of masses, recruited during a screening mammography appointment.~The second group will include 125 women presenting for diagnostic mammography and/or biopsy appointment with known masses identified on mammogram, ultrasound or both.~Both groups will receive breast cancer screening with mammography and SureTouch.
Study NCT04347278 — intervention group
Intervention type: DRUG
Intervention: Patients with the treatment agains COVID19
Description: Data will be collected from patients who receive any of the treatments included in the Technical Document. Manejo clínico del COVID-19: tratamiento médico of the Ministry of Health, and Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2 of the AEMPS, either as antivirals or as treatment of the inflammatory process in patients with SARS, or others as they arise.
Study NCT02759562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Administered via subcutaneous injection
Study NCT02759562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered via subcutaneous injection
Study NCT02759562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection
Study NCT01746810 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body RT and IRGA
Description: SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
Study NCT05020301 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal meditation guided audio
Description: Examining DMN connectivity and CSF flow in external meditation state by Internal Meditation Instruction Audio.
Study NCT04580043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.
Study NCT04580043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habit Override Practice
Description: Computerized brain training to provide practice in overriding avoidance habits.
Study NCT04580043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Study NCT04580043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Non-invasive method for temporary, focal stimulation of brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Study NCT04580043 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Computer-based task practice in a non-active/inert task.
Study NCT04580043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Training
Description: Computer-based task practice in a non-active/inert task.
Study NCT04580043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Study NCT04580043 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of non-brain areas. Delivered in a continuous Theta Burst Stimulation (TBS) pattern.
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules)
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
Study NCT03240562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus anterior plane block
Description: before surgery :ultrasound-guided serratus anterior plane block
Study NCT03240562 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: patient controlled analgesia
Description: two groups have same intravenous patient controlled analgesia
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril tablets: 2.5 mg, 5 mg, 10 mg dosage strengths
Study NCT03240562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia
Description: two groups have same intravenous patient controlled analgesia
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril
Study NCT02678312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), tablets: 50 mg, 100 mg, 200 mg dosage strengths
Study NCT04946162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil Pill
Description: Each patient will be given tadalafil 40 mg one time
Study NCT02549963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Left Atrial Appendage Occlusion Device
Study NCT02549963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Study NCT02359032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6858
Description: Oral tablets
Study NCT04297410 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-I&T Radionuclide
Description: Each patient will receive two single doses of 7.4 GBq 177-Lu-PSMA-I\&T treatments. The treatments will be given intravenously, 2 weeks apart starting 12 weeks prior to radical prostatectomy.
Study NCT03628599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Water Gradient silicon hydrogel daily disposable contact lenses
Study NCT03628599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Silicon hydrogel daily disposable contact lenses with HydraLuxe™ Technology
Study NCT02043171 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A Placebo comparator
Study NCT02359032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT02359032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study NCT02598141 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sampling grinding
Description: One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
Study NCT02043171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMB plus Vitamin D
Description: Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
Study NCT02043171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Exercise
Description: This group will not participate in 3 times per week strength training
Study NCT02043171 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Non-Exercise
Description: This group will not participate in 3 times per week strength training
Study NCT02598141 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological sampling with standard procedures
Description: One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
Study NCT02043171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: This group will participate in a supervised 3 times per week strength training program
Study NCT02043171 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: This group will participate in a supervised 3 times per week strength training program
Study NCT04638933 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01550289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
Description: 0.5 mL, Subcutaneous
Study NCT01550289 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: NaCl 0.9% solution
Description: 0.5 ml, Subcutaneous
Study NCT03267706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palliative Care Comprehensive Tool
Description: Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
Study NCT03090802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring Adolescent Mothers at School (MAMAS)
Description: Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
Study NCT01897844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 (100, 2000, 3000 mcg bid)
Study NCT04578119 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sliding Intubating Technique
Description: Sliding technique' means that endotracheal intubation is performed by sliding the videolayngoscope blade under the epiglottis smoothly.
Study NCT01797445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Study NCT01797445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TDF
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Study NCT01797445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TDF Placebo
Description: Tablet administered orally once daily
Study NCT01797445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E/C/F/TAF Placebo
Description: Tablet administered orally once daily
Study NCT01897844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00933192 — intervention group
Intervention type: DEVICE
Intervention: Siemens Acuson Antares ultrasound
Description: skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
Study NCT01933061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
Study NCT01933061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Abraxane 150 mg/m\^2 intravenously on Days 1, 8, and 15 of a 28-day cycle